In This Article:
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below.
Johnson & Johnson (NYSE:JNJ) researches, develops, manufactures and sells various products in the health care field worldwide.
It is set to report its Q1 2025 earnings on April 15. Wall Street analysts expect the company to post an EPS of $2.67, down from $2.71 in the year-ago period. According to Benzinga Pro, quarterly revenue is expected to reach $22.04 billion, up from $21.38 billion in the previous year.
If You Bought Johnson & Johnson Stock 10 Years Ago
The company's stock traded at approximately $102.26 per share 10 years ago. If you had invested $10,000, you could have bought roughly 98 shares. Currently, shares trade at $146.64, meaning your investment's value could have grown to $14,340 from stock price appreciation alone. However, Johnson & Johnson also paid dividends during these 10 years.
Don't Miss:
-
Unlock the hidden potential of commercial real estate — This platform allows individuals to invest in commercial real estate offering a 12% target yield with a bonus 1% return boost today!
-
This Jeff Bezos-backed startup will allow you to become a landlord in just 10 minutes, with minimum investments as low as $100.
Johnson & Johnson's dividend yield is currently 3.38%. Over the last 10 years, it has paid about $37.93 in dividends per share, which means you could have made $3,709 from dividends alone.
Summing up $14,340 and $3,709, we end up with the final value of your investment, which is $18,049. This is how much you could have made if you had invested $10,000 in Johnson & Johnson stock 10 years ago. This means a total return of 80.49%. However, this figure is significantly less than the S&P 500 total return for the same period, which was 237.69%.
Trending: It’s no wonder Jeff Bezos holds over $70 million in art — this alternative asset has outpaced the S&P 500 since 1995, delivering an average annual return of 11.4%. Here’s how everyday investors are getting started.
What Could The Next 10 Years Bring?
Johnson & Johnson has a consensus rating of "Neutral" and a price target of $164.68 based on the ratings of 22 analysts. The price target implies more than a 12% upside from the current stock price.
On Jan. 22, the company announced its Q4 2024 earnings, posting an adjusted EPS of $2.04, down 10.9% year-over-year, beating the consensus of $2.01, as reported by Benzinga.
The pharmaceutical giant reported sales of $22.52 billion, up 5.3% year-over-year, beating the consensus of $22.44 billion. Operational growth was 6.7% and adjusted operational growth was 5.7%.